FUS and amyotrophic lateral sclerosis: An ongoing, pivotal, phase 3 clinical study of ION363 (NCT04768972) will determine whether this antisense therapeutic provides any clinical benefit of slowing disease progression in symptomatic patients with ALS-FUS.